Evaluating First Drug to Show Improvement in Subtype of ASD

Discuss autism theories, media stories, and efforts to put ASD on the government agenda here.

Moderator: ModeratorBill

Forum rules
Please limit quotes from articles to five paragraphs. Also, researchers may post study information here.
BTDT
Posts: 3492
Joined: Tue Dec 20, 2005 8:02 pm

Evaluating First Drug to Show Improvement in Subtype of ASD

Postby BTDT » Wed Apr 25, 2012 8:19 pm

Evaluating the First Drug to Show Improvement in Subtype of Autism

ScienceDaily (Apr. 24, 2012) — In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

This study builds on findings announced by the researchers in 2010, which showed that after two weeks of treatment with IGF-1 in a mouse model, deficits in nerve cell communication were reversed and deficiencies in adaptation of nerve cells to stimulation, a key part of learning and memory, were restored.


Article continues at link

Return to “Autism Articles, Studies & Politics”